A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2009
11/26/2009	CA2724737A1 Pyrimidine non-classical cannabinoid compounds and related methods of use
11/26/2009	CA2724733A1 Pyrimidine classical cannabinoid compounds and related methods of use
11/26/2009	CA2724728A1 Pyridine non-classical cannabinoid compounds and related methods of use
11/26/2009	CA2724715A1 Heterocycles as protein kinase inhibitors
11/26/2009	CA2724697A1 Pyridine classical cannabinoid compounds and related methods of use
11/26/2009	CA2724594A1 Niacin and nsaid combination therapy
11/26/2009	CA2724592A1 Agent for maintenance of induced remission
11/26/2009	CA2724584A1 Phenyl or pyridinyl substituted indazoles derivatives
11/26/2009	CA2724569A1 Compositions and methods to protect cells by blocking entry of pathogen proteins
11/26/2009	CA2724550A1 Combination antitumor therapy
11/26/2009	CA2724508A1 Phenyl and benzodioxinyl substituted indazoles derivatives
11/26/2009	CA2724474A1 Therapeutic prostaglandin compounds used as ocular hypotensive agents
11/26/2009	CA2724467A1 Therapeutic lactams
11/26/2009	CA2724430A1 Heterocyclic compounds as factor ixa inhibitors
11/26/2009	CA2724426A1 Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
11/26/2009	CA2724412A1 Maintenance therapy regimen for treating acne
11/26/2009	CA2724408A1 Methods and compositions comprising novel cationic lipids
11/26/2009	CA2724357A1 Novel thiophenediamine derivative having urea structure
11/26/2009	CA2724011A1 Gpr119 receptor agonists
11/26/2009	CA2723961A1 Phosphorous derivatives as kinase inhibitors
11/26/2009	CA2723954A1 Pharmaceutical compositions having carboxyvinyl polymer and povidone polymer
11/26/2009	CA2723949A1 Methods for reducing lipid absorption by an animal
11/26/2009	CA2723769A1 Anhydrous and hydrate forms of crystalline 2-((2s, 3r, 4e, 6e, 1oe, 12 s)-13-(4-fluorophenoxy)-2,3, 12-(trihydroxytrideca-4, 6, 10-trien-8- ynyl)oxy) acetic acid
11/26/2009	CA2723612A1 Tetrahydroisoquinolines as antimalarial agents
11/26/2009	CA2723596A1 Novel [f-18]-labelled l-glutamic acid and l-glutamine derivatives (i), their use and processes for their preparation
11/26/2009	CA2723594A1 {f-19}-labeled l-glutamic acid and l-glutamine derivative (iii), use thereof and method for obtaining them
11/26/2009	CA2723459A1 Novel [f-18]-labelled l-glutamic acid and l-glutamine derivatives (ii), their use and processes for their preparation
11/26/2009	CA2722845A1 Pharmaceutical composition for the treatment of premature ejaculation
11/26/2009	CA2721710A1 Triazine compounds as pi3 kinase and mtor inhibitors
11/26/2009	CA2721692A1 Triazine compounds as p13 kinase and mtor inhibitors
11/26/2009	CA2721102A1 Process for the preparation of prostaglandin analogues and intermediates thereof
11/26/2009	CA2720729A1 Novel macrocyclic inhibitors of hepatitis c virus replication
11/26/2009	CA2720664A1 Novel compositions which inhibit melanogenesis and uses thereof
11/26/2009	CA2718918A1 Methods for treating or preventing colorectal cancer
11/26/2009	CA2688469A1 2,5-disubstituted imidazo[4,5-c]pyridines for treating muscular dystrophy
11/25/2009	EP2123759A2 Stabilized RNAS as transfection controls and silencing reagents
11/25/2009	EP2123757A1 5` triphosphate oligonucleotide with blunt end and uses thereof
11/25/2009	EP2123752A2 Novel nucleic acid
11/25/2009	EP2123672A1 Modulation of IL-2- and IL-15- mediated T cell responses
11/25/2009	EP2123665A2 Inhibitors of interleukin-1Beta converting enzyme
11/25/2009	EP2123664A1 Novel sugar-linked chlorin derivative and process for production thereof
11/25/2009	EP2123663A1 Method for production of sugar oxazoline derivative
11/25/2009	EP2123662A1 Trehalose compound, process for production of the compound, and immuno-stimulative agent comprising the compound
11/25/2009	EP2123656A1 Process for production of prasugrel hydrochloride having high purity
11/25/2009	EP2123655A1 Bis(tetrahydrofuran) compound, method for production of the compound, and use of the compound
11/25/2009	EP2123654A1 Pyrazolopyrimidine compound
11/25/2009	EP2123652A1 Heterocyclic compound
11/25/2009	EP2123651A1 Condensed pyridine compound
11/25/2009	EP2123650A1 Novel form of tiotropium bromide and process for preparation thereof
11/25/2009	EP2123649A1 3-pyrrolo-cyclohexylene-2-dihydro-indolinone derivatives and uses thereof
11/25/2009	EP2123647A1 2-(amino-substituted)-4-phenyl pyrimidines useful for treating inflammatory diseases
11/25/2009	EP2123644A1 Benzoxazepine derivatives and use thereof
11/25/2009	EP2123643A1 Novel prophylactic and/or therapeutic agent for diabetic neuropathy
11/25/2009	EP2123642A1 Novel prophylactic and/or therapeutic agent for neurogenic pain
11/25/2009	EP2123637A1 Novel curcumin derivative
11/25/2009	EP2123636A1 Method for producing aminoacetylpyrrolidinecarbonitrile derivative
11/25/2009	EP2123630A1 2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative
11/25/2009	EP2123628A1 A process for preparing optical pure milnacipran and its pharmaceutically accepted salts
11/25/2009	EP2123621A1 New [F-18]-marked L-glutamic acids and L-glutamic acid derivatives (1), application thereof and method for their manufacture
11/25/2009	EP2123620A1 {F-19}-labeled L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them
11/25/2009	EP2123619A1 New [F-18]-marked L-glutamic acids and L-glutamic acid derivatives (II), application thereof and method for their manufacture
11/25/2009	EP2123303A1 Ameliorating agent for insulin resistance
11/25/2009	EP2123301A1 Therapeutic agent for urinary tract disease
11/25/2009	EP2123296A1 Adjuvant for transdermal or transmucosal administration and pharmaceutical preparation containing the same
11/25/2009	EP2123295A1 Therapeutic agent for interstitial pneumonia
11/25/2009	EP2123288A1 C<sb>70</sb>-containing liposome, method for producing the same, and use of the same
11/25/2009	EP2123287A1 Agent for preventing bleeding from cerebral cortical vein
11/25/2009	EP2123286A1 A nanoparticle of glucidamin for treating tumor and preparation method thereof
11/25/2009	EP2123285A1 Nucleosidic phosphoantigens for use in VGAMMA9DELTA2 T cell-mediated therapy
11/25/2009	EP2123284A1 Prophylactic and/or therapeutic agent for cardiac infarction
11/25/2009	EP2123283A1 The tetracyclic anthraquinones possessing anti-cancer effect
11/25/2009	EP2123282A2 Immunemodulating oligosaccharides
11/25/2009	EP2123281A1 Composition for prevention or treatment of disease associated with amyloidosis through inhibition of aggregation amyloid protein and through promotion of degradation of amyloid protein
11/25/2009	EP2123280A1 Agent for prevention and/or treatment of systemic lupus erythematosus
11/25/2009	EP2123279A1 Sequential application of 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on and one or more gestagens for treating gynaecological illnesses
11/25/2009	EP2123278A1 Eye drop reparation comprising latanoprost
11/25/2009	EP2123277A1 Preventive or therapeutic agent for inflammatory bowel disease
11/25/2009	EP2123276A1 Pharmaceutical composition comprising pyrazine derivative, and method of using pyrazine derivative in combination
11/25/2009	EP2123275A1 Process for production of buprenorphine pharmaceutical preparation to be applied to mouth mucosa
11/25/2009	EP2123274A1 Medicinal composition for transdermal absorption, medicinal composition storing unit and transdermal absorption preparation using the same
11/25/2009	EP2123273A1 Therapeutic agent for urinary excretion disorder
11/25/2009	EP2123272A1 Adam inhibitor
11/25/2009	EP2123271A1 Drug for treatment of influenza
11/25/2009	EP2123270A1 Iron metabolism-improving agent
11/25/2009	EP2123269A1 Nanoparticles functionalized with sulfated amino alcohols for the inhibition of selectin-mediated cell adhesion
11/25/2009	EP2123268A1 Pharmaceutical composition for prevention or treatment of disease associated with tear reduction
11/25/2009	EP2123267A1 Novel compositions and methods for treating hyperproliferative diseases
11/25/2009	EP2123266A1 Cancer therapeutic agent and anti-carcinogenic agent
11/25/2009	EP2123265A1 Endipalene formulations in the treatment of psoriasis
11/25/2009	EP2123264A1 Heterocyclic derivatives as abnormal cannabidiols agents for lowering intraocular pressure
11/25/2009	EP2123263A1 Composition and method for suppressing lipid peroxidation in erythrocytes
11/25/2009	EP2123262A1 Polyelectrolyte-encapsulated gold nanoparticles capable of crossing blood-brain barrier
11/25/2009	EP2123260A1 Liposome formulation and process for preparation thereof
11/25/2009	EP2123258A1 Liposomes for drug delivery
11/25/2009	EP2123257A2 Stable high Vitamin C content polyol-in-oil emulsified system and its preparation
11/25/2009	EP2123255A1 Pharmaceutical composition containing fine particle oil-based suspension
11/25/2009	EP2123254A1 Composition for external application to skin
11/25/2009	EP2123253A1 Wrinkling-preventing and -modifying agent
11/25/2009	EP2123252A1 Method for increasing hair growth
11/25/2009	EP2123251A1 Composition for external application to skin

1 ... 2486 2487 2488 2489 2490 2491 2492 2493 2494 2495 2496 2497 2498 2499 2500 2501 2502 2503 2504 2505 2506 ... 7860